Publications

  • Keyao Pan, Jinxue Long, Haoxin Sun, Gregory J. Tobin, Peter L. Nara, Michael W. Deem
    Selective Pressure to Increase Charge in Immunodominant Epitopes of the H3 Hemagglutinin Influenza Protein
    J Mol Evol. 2011 January; 72(1): 90–103. Published online 2010 November 18.
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033527/?tool=pmcentrez

  • Wolfram JH, Nara PL. Exchange and sharing of new information, experiences, and approaches to controlling, reducing, and eventually eradicating different types of diseases. Conclusion. Vaccine. 2010 Oct 1;28 Suppl 5:F85-8. No abstract available.
    http://www.ncbi.nlm.nih.gov/pubmed/20891047  

  • Wolfram JH, Nara PL.
    Brucellosis as a Transboudary Infection of Animals and Humans which Needs to be Managed by Cooperative Efforts of Different Countries. Introduction. Vaccine. 2010 Oct 1;28 Suppl 5:F1-2.
    http://www.ncbi.nlm.nih.gov/pubmed/20850687

  • Eguchi-Ogawa T, Wertz N, Sun XZ, Puimi F, Uenishi H, Wells K, Chardon P, Tobin GJ, Butler JE.
    Antibody repertoire development in fetal and neonatal piglets. XI. The relationship of variable heavy chain gene usage and the genomic organization of the variable heavy chain locus.
    J Immunol. 2010 Apr 1;184(7):3734-42. Epub 2010 Mar 5.
    http://www.ncbi.nlm.nih.gov/pubmed/20207992

    •
  • Sponseller BA, Strait E, Jergens A, Trujillo J, Harmon K, Koster L, Jenkins-Moore M, Killian M, Swenson S, Bender H, Waller K, Miles K, Pearce T, Yoon KJ, Nara P. Influenza A pandemic (H1N1) 2009 virus infection in domestic cat.
    Emerg Infect Dis. 2010 Mar;16(3):534-7.
    http://www.ncbi.nlm.nih.gov/pubmed/20202440

  • Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J, Barrera J, Pena L, Grubman, MJ and Nara PL.
    Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26:6189-6199, 2008.
    http://www.ncbi.nlm.nih.gov/pubmed/18852005

    •
  • Nara PL, Nara D, Chaudhuri AR, Lin G, and Tobin GJ
    Perspectives on advancing preventative medicine through vaccinology at the comparative veterinary, human and conservation medicine interface: Not missing the opportunities. Vaccine 26:6200-6211, 2008.
    http://www.ncbi.nlm.nih.gov/pubmed/18708109

    •
  • Gay CG, Richie TL, Pastoret PP, Minguez-Tudela I, de Baetselier P, Göbel T, Goddeeris B, Kaiser P, Morrison I, Sánchez-Vizcaíno JM, Anderson K, Baillie LW, Brown WC, Estes DM, Herrera E, Nara PL, Ockenhouse CF, Roth JA, Sztein MB.    Advances in immunology and vaccine discovery report of the United States-European Commission workshop.
    Vaccine. 2007 Oct 10;25(41):7007-11. Epub 2007 Aug 6.
    http://www.ncbi.nlm.nih.gov/pubmed/17728022

  • Nara PL. The status and role of vaccines in the U.S. food animal industry. Implications for biological terrorism.
    Ann N Y Acad Sci. 1999;894:206-17. Review.
    http://www.ncbi.nlm.nih.gov/pubmed/10681992

  • Kohler H, Muller S, Schiffer M, Nara PL. Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies
    J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):315-6.
    http://www.ncbi.nlm.nih.gov/pubmed/10077183

    •
  • Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
    J Immunol. 1997 Jul 1;159(1):279-89.
    http://www.ncbi.nlm.nih.gov/pubmed/9200464

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

dreamstime_13272506Biological Mimetics, Inc. research and development includes veterinary applications such as:
Foot and Mouth Disease Virus , Infectious Pancreatic Necrosis Virus,
and Porcine Reproductive and Respiratory Syndrome Virus.

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza